MaterialsWaltham, Massachusetts, United StatesFounded 2019· One of 961 Materials companies tracked by AMPulse
FluidForm develops FRESH bioprinting technology enabling 3D printing of complex soft tissues and organs for regenerative medicine.
CEO / Founder
Michael Graffeo
Team Size
11-50
Stage
Active
Total Funding
$5M
Latest Round
Venture Round
Key Investors
1945 Capital, Hackensack Meridian Health, U.S. Department of Health and Human Services, NSF, Mountain State Capital, Crowdfunding
Technology & Products
Key Products
FRESH™ 3D bioprinting technology, LifeSupport™ Gelatin Microparticle support bath
Technological Advantage
Patented FRESH (Freeform Reversible Embedding of Suspended Hydrogels) technology from Carnegie Mellon
Differentiation
Value Proposition
FRESH technology enables bioprinting of soft tissues that maintain their shape during printing using gel support bath.
How They Differentiate
Unique gel support enables soft tissue geometries impossible with standard bioprinting approaches
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, tissue engineering labs, medical device companies
Industry Verticals
Life Sciences, Tissue Engineering, Drug Discovery, Regenerative Medicine
Competitors
CELLINK/Cytiva, Organovo, Allevi/3D Systems
Growth & Milestones
Growth Metrics
$14.5M total funding raised since 2018; $4.5M raised in 2024; 2025 crowdfunding campaign on StartEngine at $25M valuation cap; Revenue $168K (R&D stage company)
Major Milestones
2018: Founded in Waltham, MA; Developed FRESH 3D bioprinting platform; Raised seed funding from 1945 Capital; 2024: Raised $4.5M; 2025-04: Launched $1.24M StartEngine crowdfunding; 2025-07: Presented 6-month efficacy data at IPITA and ADA conferences
FluidForm develops bioprinting technology for regenerative medicine, specifically targeting the challenge of printing soft tissues that collapse under their own weight. Its FRESH (Freeform Reversible Embedding of Suspended Hydrogels) process, invented at Carnegie Mellon University, deposits hydrogel bioinks into a thermoreversible gelatin microparticle support bath. The support gel holds printed structures in place during fabrication and is later melted away, leaving intact tissue constructs with complex geometries such as vascular networks.
The company's core product is the FRESH bioprinting platform, sold alongside LifeSupport Gelatin Microparticle support bath. Target customers include research institutions, pharmaceutical companies, tissue engineering labs, and medical device firms. Named customers include Ethicon (Johnson & Johnson) and LulzBot. FluidForm competes with CELLINK/Cytiva, Organovo, and Allevi/3D Systems, but differentiates through its embedded printing approach that enables soft tissue geometries impossible with standard extrusion bioprinting.
FluidForm was founded in 2019 and is headquartered in Waltham, Massachusetts. It has raised approximately $14.5 million since 2018, including $4.5 million in 2024 and a 2025 StartEngine crowdfunding campaign at a $25 million valuation cap. The company remains at an R&D stage with $168,000 in revenue. Key investors include 1945 Capital, Hackensack Meridian Health, the U.S. Department of Health and Human Services, the NSF, Mountain State Capital, and crowdfunding backers. CEO Michael Graffeo is a former Carnegie Mellon professor and inventor of the FRESH technology.
A strategic moat lies in the patented FRESH process and its ability to print vascularized tissue constructs, a critical requirement for functional organ fabrication. However, the company faces the long commercialization timeline typical of regenerative medicine, with regulatory hurdles and the need to demonstrate in vivo efficacy at scale. Recent 2025 data presented at IPITA and ADA conferences showing six-month efficacy in preclinical models suggests progress, but revenue remains minimal, and the path to clinical adoption is uncertain.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights